In an expansion of their deal to develop inhaled insulin, Eli Lilly and Co. is buying $30 million in newly issued convertible preferred stock from Alkermes Inc., which will use the money to pay for the joint development program for 2003 and 2004. (BioWorld Today) Read More
While politicians in Washington haven't decided whether they should ban therapeutic cloning, scientists in California have forged ahead with a plan to establish a research institute that will use stem cell biology to study cancer and other diseases. Read More
